In response: Letter on update to the Vitamin C, Thiamine and Steroids in Sepsis (VICTAS) protocol.

• Type of Material: Article
• Authors: Christopher J. Lindsell, Vanderbilt University; Anna McGlothlin, Berry Consultants LLC; Samuel Nwosu, Vanderbilt University; Todd W. Rice, Vanderbilt University; Alex Hall, Emory University; Gordon R. Bernard, Vanderbilt University; Laurence W. Busse, Emory University; E. Wesley Ely, Vanderbilt University; Alpha A. Fowler, Virginia Commonwealth University; David F. Gaieski, Thomas Jefferson University; Jeremiah S. Hinson, Johns Hopkins University; Michael H. Hooper, Vanderbilt University; James C. Jackson, Vanderbilt University; Gabor D. Kelen, Johns Hopkins University; Mark Levine, National Institute of Diabetes and Digestive and Kidney Diseases; Gregory Martin, Emory University; Richard E. Rothman, Johns Hopkins University; Jonathan E. Sevransky, Emory University; Kert Viele, Berry Consultants LLC; David Wright, Emory University; David N. Hager, Vanderbilt University
• Language: English
• Date: 2020-04-22
• Publisher: BMC (part of Springer Nature)
• Publication Version: Final Published Version
• Copyright Statement: © The Author(s) 2020
• License: Creative Commons Attribution 4.0 International
• Final Published Version (URL): http://dx.doi.org/10.1186/s13063-020-04290-6
• Title of Journal or Parent Work: Trials
• ISSN: 1745-6215
• Volume: 21
• Issue: 1
• Start Page: 351
• End Page: 351
• Grant/Funding Information: EWE reports funding for the VICTAS trial to his institution from the Marcus Foundation and has received honoraria from Pfizer, Orion, and Masimo for continuing medical education activities (no speakers’ bureaus or stocks, etc.).; Funding for VICTAS was provided by the Marcus Foundation via contract to Emory University, the study sponsor. Neither the sponsor nor the funding agency has had any role in the design, execution, or planned analyses for this study. They have had no input on the writing of this letter and will have no input to future updates of the statistical analysis plan. Point-of-care glucometers were loaned to some study sites by Nova Biomedical, which has had no role in the design, execution, or planned analyses of the study, nor the writing of this letter.; ML is supported by the Intramural Research Program, NIDDK, NIH. DK053212–12: Ascorbic acid as a pharmacologic agent in disease treatment.; GSM reports grants for the VICTAS Trial to his institution from the Marcus Foundation as well as grants from National Institutes of Health (NIH), Biomedical Advanced Research and Development Authority (BARDA) and Bristol-Myers Squibb to his institution.; AH reports funding for the VICTAS trial to his institution from the Marcus Foundation as well as grants from the National Institutes of Health (NIH), Cerenovus, Sense Diagnostics, and the NICO Corporation.; SN, GRB, DNH, JSH, REM, TR, and RER report funding for the VICTAS trial to their institutions from the Marcus Foundation.
• Research Categories: Health Sciences, Nutrition

Abstract

TRIAL REGISTRATION: ClinicalTrials.gov: NCT03509350. Registered on 26 April 2018.